
## Christopher L King

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9035662/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	<i>Plasmodium vivax</i> clinical malaria is commonly observed in Duffy-negative Malagasy people. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 5967-5971.	3.3	332
2	Plasmodium vivax Invasion of Human Erythrocytes Inhibited by Antibodies Directed against the Duffy Binding Protein. PLoS Medicine, 2007, 4, e337.	3.9	161
3	Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis. Clinical Infectious Diseases, 2016, 62, 334-341.	2.9	160
4	Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage <i>Plasmodium vivax</i> infection. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 8363-8368.	3.3	147
5	A Trial of a Triple-Drug Treatment for Lymphatic Filariasis. New England Journal of Medicine, 2018, 379, 1801-1810.	13.9	132
6	Can Prenatal Malaria Exposure Produce an Immune Tolerant Phenotype?: A Prospective Birth Cohort Study in Kenya. PLoS Medicine, 2009, 6, e1000116.	3.9	131
7	CD28 activation promotes Th2 subset differentiation by human CD4+ cells. European Journal of Immunology, 1995, 25, 587-595.	1.6	119
8	Fy <sup>a</sup> /Fy <sup>b</sup> antigen polymorphism in human erythrocyte Duffy antigen affects susceptibility to <i>Plasmodium vivax</i> malaria. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 20113-20118.	3.3	116
9	Do Antenatal Parasite Infections Devalue Childhood Vaccination?. PLoS Neglected Tropical Diseases, 2009, 3, e442.	1.3	115
10	Acquired Immune Responses to <i>Plasmodium falciparum</i> Merozoite Surface Protein-1 in the Human Fetus. Journal of Immunology, 2002, 168, 356-364.	0.4	100
11	Strain-Specific Duffy Binding Protein Antibodies Correlate with Protection against Infection with Homologous Compared to Heterologous <i>Plasmodium vivax</i> Strains in Papua New Guinean Children. Infection and Immunity, 2009, 77, 4009-4017.	1.0	84
12	Natural Acquisition of Immunity to Plasmodium vivax. Advances in Parasitology, 2013, 81, 77-131.	1.4	84
13	Distinct Th1- and Th2-Type Prenatal Cytokine Responses to Plasmodium falciparum Erythrocyte Invasion Ligands. Infection and Immunity, 2005, 73, 3462-3470.	1.0	83
14	CD28-deficient mice generate an impaired Th2 response toSchistosoma mansoni infection. European Journal of Immunology, 1996, 26, 2448-2455.	1.6	76
15	Prenatal T Cell Immunity toWuchereria bancroftiand Its Effect on Filarial Immunity and Infection Susceptibility during Childhood. Journal of Infectious Diseases, 2006, 193, 1005-1013.	1.9	75
16	The Impact of Repeated Rounds of Mass Drug Administration with Diethylcarbamazine Plus Albendazole on Bancroftian Filariasis in Papua New Guinea. PLoS Neglected Tropical Diseases, 2008, 2, e344.	1.3	74
17	Reduced BNT162b2 Messenger RNA Vaccine Response in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Naive Nursing Home Residents. Clinical Infectious Diseases, 2021, 73, 2112-2115.	2.9	69
18	The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study, PL oS Medicine, 2019, 16, e1002839	3.9	66

CHRISTOPHER L KING

#	Article	IF	CITATIONS
19	Identification of highly-protective combinations of Plasmodium vivax recombinant proteins for vaccine development. ELife, 2017, 6, .	2.8	64
20	Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa. PLoS Neglected Tropical Diseases, 2017, 11, e0005163.	1.3	63
21	Antibody-Dependent Transplacental Transfer of Malaria Blood-Stage Antigen Using a Human Ex Vivo Placental Perfusion Model. PLoS ONE, 2009, 4, e7986.	1.1	53
22	Epitope-Specific Humoral Immunity to Plasmodium vivax Duffy Binding Protein. Infection and Immunity, 2003, 71, 2508-2515.	1.0	50
23	Risk factors for malaria and adverse birth outcomes in a prospective cohort of pregnant women resident in a high malaria transmission area of Papua New Guinea. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2015, 109, 313-324.	0.7	45
24	Biosignatures of Exposure/Transmission and Immunity. American Journal of Tropical Medicine and Hygiene, 2015, 93, 16-27.	0.6	45
25	Naturally Acquired Binding-Inhibitory Antibodies to <i>Plasmodium vivax</i> Duffy Binding Protein and Clinical Immunity to Malaria in Rural Amazonians. Journal of Infectious Diseases, 2016, 214, 1539-1546.	1.9	42
26	Prenatal Malaria Immune Experience Affects Acquisition of <i>Plasmodium falciparum</i> Merozoite Surface Protein-1 Invasion Inhibitory Antibodies during Infancy. Journal of Immunology, 2006, 177, 7139-7145.	0.4	38
27	Population genomics of the filarial nematode parasite <i>Wuchereria bancrofti</i> from mosquitoes. Molecular Ecology, 2016, 25, 1465-1477.	2.0	38
28	An overview of animal models in experimental schistosomiasis and refinements in the use of non-human primates. Laboratory Animals, 2001, 35, 205-212.	0.5	35
29	An engineered vaccine of the Plasmodium vivax Duffy binding protein enhances induction of broadly neutralizing antibodies. Scientific Reports, 2017, 7, 13779.	1.6	33
30	Efficacy and Safety of a Single Dose of Ivermectin, Diethylcarbamazine, and Albendazole for Treatment of Lymphatic Filariasis in CÁ´te d'Ivoire: An Open-label Randomized Controlled Trial. Clinical Infectious Diseases, 2020, 71, e68-e75.	2.9	32
31	Associations between an IgG3 polymorphism in the binding domain for FcRn, transplacental transfer of malaria-specific IgG3, and protection against Plasmodium falciparum malaria during infancy: A birth cohort study in Benin. PLoS Medicine, 2017, 14, e1002403.	3.9	32
32	Cloning, sequencing, and homology analysis of nonhuman primate Fas/Fas-ligand and co-stimulatory molecules. Immunogenetics, 2001, 53, 315-328.	1.2	31
33	Amplification of Duffy binding protein-encoding gene allows Plasmodium vivax to evade host anti-DBP humoral immunity. Nature Communications, 2020, 11, 953.	5.8	31
34	Significant Reduction in Vaccine-Induced Antibody Levels and Neutralization Activity Among Healthcare Workers and Nursing Home Residents 6 Months Following Coronavirus Disease 2019 BNT162b2 mRNA Vaccination. Clinical Infectious Diseases, 2022, 75, e884-e887.	2.9	31
35	Single-Dose Triple-Drug Therapy for <i>Wuchereria bancrofti</i> — 5-Year Follow-up. New England Journal of Medicine, 2020, 382, 1956-1957.	13.9	30
36	Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in Côte d'Ivoire. PLoS Neglected Tropical Diseases, 2019, 13, e0007325.	1.3	29

Christopher L King

#	Article	IF	CITATIONS
37	Identification and Characterization of Functional Human Monoclonal Antibodies to <i>Plasmodium vivax</i> Duffy-Binding Protein. Journal of Immunology, 2019, 202, 2648-2660.	0.4	26
38	Comparison of Repeated Doses of Ivermectin Versus Ivermectin Plus Albendazole for the Treatment of Onchocerciasis: A Randomized, Open-label, Clinical Trial. Clinical Infectious Diseases, 2020, 71, 933-943.	2.9	21
39	Increased Levels of Soluble Interleukinâ€4 Receptor in the Sera of Patients with Visceral Leishmaniasis. Journal of Infectious Diseases, 1999, 179, 743-746.	1.9	20
40	The safety of combined triple drug therapy with ivermectin, diethylcarbamazine and albendazole in the neglected tropical diseases co-endemic setting of Fiji: AÂcluster randomised trial. PLoS Neglected Tropical Diseases, 2020, 14, e0008106.	1.3	17
41	P. falciparum infection and maternofetal antibody transfer in malaria-endemic settings of varying transmission. PLoS ONE, 2017, 12, e0186577.	1.1	17
42	Does a lack of vaccine side effects correlate with reduced BNT162b2 mRNA vaccine response among healthcare workers and nursing home residents?. Aging Clinical and Experimental Research, 2021, 33, 3151-3160.	1.4	16
43	Finding the sweet spots of inhibition: Understanding the targets of a functional antibody against Plasmodium vivax Duffy binding protein. International Journal for Parasitology, 2012, 42, 1055-1062.	1.3	15
44	Fine Specificity of Plasmodium vivax Duffy Binding Protein Binding Engagement of the Duffy Antigen on Human Erythrocytes. Infection and Immunity, 2012, 80, 2920-2928.	1.0	14
45	A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases, 2021, 15, e0009002.	1.3	14
46	Systems analysis-based assessment of post-treatment adverse events in lymphatic filariasis. PLoS Neglected Tropical Diseases, 2019, 13, e0007697.	1.3	13
47	Safety and efficacy of mass drug administration with a single-dose triple-drug regimen of albendazole + diethylcarbamazine + ivermectin for lymphatic filariasis in Papua New Guinea: An open-label, cluster-randomised trial. PLoS Neglected Tropical Diseases, 2022, 16, e0010096.	1.3	13
48	Dosing pole recommendations for lymphatic filariasis elimination: A height-weight quantile regression modeling approach. PLoS Neglected Tropical Diseases, 2019, 13, e0007541.	1.3	12
49	HIV, Cytomegalovirus, and Malaria Infections during Pregnancy Lead to Inflammation and Shifts in Memory B Cell Subsets in Kenyan Neonates. Journal of Immunology, 2019, 202, 1465-1478.	0.4	10
50	Changes in Cytokine, Filarial Antigen, and DNA Levels Associated With Adverse Events Following Treatment of Lymphatic Filariasis. Journal of Infectious Diseases, 2018, 217, 280-287.	1.9	9
51	Is ivermectin safe in pregnancy?. The Lancet Global Health, 2020, 8, e12-e13.	2.9	8
52	Mass drug administration of ivermectin, diethylcarbamazine, plus albendazole compared with diethylcarbamazine plus albendazole for reduction of lymphatic filariasis endemicity in Papua New Guinea: a cluster-randomised trial. Lancet Infectious Diseases, The, 2022, 22, 1200-1209.	4.6	8
53	Liquid chromatography–mass spectrometry analysis of diethylcarbamazine in human plasma for clinical pharmacokinetic studies. Journal of Pharmaceutical and Biomedical Analysis, 2014, 98, 307-310.	1.4	7
54	Pharmacokinetic and safety study of co-administration of albendazole, diethylcarbamazine, Ivermectin and azithromycin for the integrated treatment of Neglected Tropical Diseases. Clinical Infectious Diseases, 2020, , .	2.9	7

CHRISTOPHER L KING

0

#	Article	IF	CITATIONS
55	Community control strategies for scabies: A cluster randomised noninferiority trial. PLoS Medicine, 2021, 18, e1003849.	3.9	7
56	Hypergammaglobulinemia and Impaired Transplacental Transfer of Respiratory Syncytial Virus Antibody in Papua New Guinea. Pediatric Infectious Disease Journal, 2019, 38, e199-e202.	1.1	6
57	Naturally acquired blocking human monoclonal antibodies to Plasmodium vivax reticulocyte binding protein 2b. Nature Communications, 2021, 12, 1538.	5.8	6
58	Antibodies as epidemiological markers of genetically modified crop exposure: detection of Cry1Ab-specific IgG. Food and Agricultural Immunology, 2017, 28, 779-788.	0.7	5
59	Individual Efficacy and Community Impact of Ivermectin, Diethylcarbamazine, and Albendazole Mass Drug Administration for Lymphatic Filariasis Control in Fiji: A Cluster Randomized Trial. Clinical Infectious Diseases, 2021, 73, 994-1002.	2.9	5
60	Characterization of a novel microfilarial antigen for diagnosis of Wuchereria bancrofti infections. PLoS Neglected Tropical Diseases, 2022, 16, e0010407.	1.3	4
61	Combining different diagnostic studies of lymphatic filariasis for risk mapping in Papua New Guinea: a predictive model from microfilaraemia and antigenaemia prevalence surveys. Tropical Medicine and Health, 2018, 46, 41.	1.0	3
62	A simple, highâ€ŧhroughput and validated LCâ€MS/MS method for determination of azithromycin in human plasma and its application to a clinical pharmacokinetic study. Biomedical Chromatography, 0, , .	0.8	3
63	Semiannual Treatment of Albendazole Alone is Efficacious for Treatment of Lymphatic Filariasis: A Randomized Open-label Trial in Cote d'Ivoire. Clinical Infectious Diseases, 2021, , .	2.9	2
64	Triple-Drug Treatment Is Effective for Lymphatic Filariasis Microfilaria Clearance in Samoa. Tropical Medicine and Infectious Disease, 2021, 6, 44.	0.9	2
65	A preliminary assessment of and gene polymorphisms in Papua New Guinea - what does it mean for HIV/AIDS?. Papua and New Guinea Medical Journal, 2017, 60, 51-59.	1.0	1
66	Population Pharmacokinetics of Diethylcarbamazine in Patients with Lymphatic Filariasis and Healthy Individuals. Antimicrobial Agents and Chemotherapy, 2021, 65, e0031721.	1.4	0
67	Title is missing!. , 2020, 14, e0008106.		0
68	Title is missing!. , 2020, 14, e0008106.		0
69	Title is missing!. , 2020, 14, e0008106.		0

70 Title is missing!. , 2020, 14, e0008106.